Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
April 12 2022 - 1:20PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month April 2022
(Commission File No. 001-35193)
Grifols, S.A.
(Translation of registrant’s name into English)
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles 08174
Barcelona, Spain
(Address of registrant’s principal executive
office)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes ¨
No x
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes
¨ No x
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes
¨ No x
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82- . .
Grifols, S.A.
TABLE OF CONTENTS
![](https://content.edgar-online.com/edgar_conv_img/2022/04/12/0001104659-22-045006_tm2212570d1_6k-img001.jpg)
| Grifols, S.A.
Avinguda de la Generalitat 152-158
08174 Sant Cugat del Vallès
Barcelona - ESPAÑA
Tel. [34] 935 710 500
Fax [34] 935 710 267
www.grifols.com
Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act,
approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols")
hereby informs about the following
OTHER RELEVANT INFORMATION
As a continuation of the Inside Information notes filed by Grifols on 17 September 2021 and 26
October 2021, Grifols informs about the fulfilment of all the offer conditions with respect to the
voluntary tender offer ("VTO") launched by Grifols to acquire the remaining ordinary and
preferred shares of Biotest AG ("Biotest"), conditions which were detailed in the offer document
published on 26 October 2021 and which is available at Grifols' web site:
https://www.grifols.com/documents/3625622/3684838/OFFER-~1.PDF/cb8eca34-2b94-4afe-
8615-94f919c12024?t=1635236807904.
It is foreseen to close the share purchase agreement entered into with Tiancheng International
Investment Limited to acquire all the existing share capital of Tiancheng (Germany)
Pharmaceutical Holding AG ("HoldCo") shortly after the VTO is settled. HoldCo holds
approximately an 89.88% stake of the ordinary shares and 1.08% stake of the preferred shares of
Biotest.
In Barcelona, on 12 April 2022.
Nuria Martín Barnés
Secretary to the Board of Directors |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
Grifols, S.A. |
|
|
|
|
|
|
|
By: |
/s/ David I. Bell |
|
|
Name: |
David I. Bell |
|
|
Title: |
Authorized Signatory |
Date: April 12, 2022
Grifols (PK) (USOTC:GIKLY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Grifols (PK) (USOTC:GIKLY)
Historical Stock Chart
From Jul 2023 to Jul 2024